Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Real world study of belantamab mafodotin outcomes finds ORR 43% (21% VGPR or better), median PFS 3.8 mos, median OS 17.2 mos, median DOR 10.5 mos, reduced ORR and PFS (but better OS?) if prior BCMA tx, similar ocular tox.”
Title: Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
Authors: Malin Hultcrantz, Andriy Derkach, Hani Hassoun, Neha Korde, Kylee Maclachlan, Sham Mailankody, Dhwani Patel, Urvi A. Shah, Carlyn R. Tan, David J. Chung, Oscar B. Lahoud, Heather J. Landau, Michael Scordo, Gunjan L. Shah, David Nemirovsky, Ross S. Firestone, Theresia Akhlaghi, Tala Shekarkhand, Sergio A. Giralt, Alexander M. Lesokhin, Saad Z. Usmani
You can read the Full Article in Blood Neoplasia.
More posts featuring Robert Orlowski.
